Mega Genomics Limited (HKG:6667)
Hong Kong · Delayed Price · Currency is HKD 7.19
+0.02 (0.28%)
Sep 11, 2026, 3:51 PM HKT
Mega Genomics Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 358.37 | 247.15 | 164.23 | 151.3 | 145.73 | 237.19 | |
Revenue Growth | 159.28% | 50.49% | 8.54% | 3.82% | -38.56% | 16.71% |
Cost of Revenue | 237.47 | 129.79 | 44.88 | 63 | 64 | 70.51 |
Gross Profit | 120.9 | 117.36 | 119.35 | 88.3 | 81.72 | 166.68 |
Selling, General & Admin | 66.56 | 61.65 | 59.46 | 52.83 | 77.79 | 45.95 |
Research & Development | 16.27 | 17.29 | 19.17 | 22.38 | - | - |
Other Operating Expenses | 1.15 | 2.16 | 0.52 | 0.35 | 2.48 | 5.87 |
Operating Expenses | 94.81 | 90.79 | 71.23 | 61.58 | 106.13 | 57.98 |
Operating Income | 26.09 | 26.57 | 48.12 | 26.71 | -24.4 | 108.69 |
Interest Expense | -1.42 | -1.37 | -1.72 | -1.12 | -0.72 | -6.91 |
Interest & Investment Income | 5.26 | 6.97 | 6.08 | 6.07 | 4.01 | 2.98 |
Currency Exchange Gain (Loss) | 0.11 | 0.02 | -0.75 | 1.44 | 11.75 | - |
Other Non Operating Income (Expenses) | 1 | 1.03 | 0.1 | 3.51 | -12.06 | -8.94 |
EBT Excluding Unusual Items | 31.03 | 33.21 | 51.83 | 36.61 | -21.42 | 95.82 |
Gain (Loss) on Sale of Investments | 0.18 | 0.18 | 1.2 | -0.43 | - | 0.06 |
Other Unusual Items | -0.57 | -0.57 | 0.61 | - | - | - |
Pretax Income | 30.65 | 32.83 | 53.63 | 36.18 | -21.42 | 95.88 |
Income Tax Expense | 6.14 | 5.81 | 8.59 | 6.14 | -3.8 | 16.87 |
Net Income | 24.51 | 27.02 | 45.05 | 30.04 | -17.62 | 79.02 |
Net Income to Common | 24.51 | 27.02 | 45.05 | 30.04 | -17.62 | 79.02 |
Net Income Growth | -30.64% | -40.01% | 49.96% | - | - | -0.10% |
Shares Outstanding (Basic) | 197 | 197 | 207 | 212 | 206 | 127 |
Shares Outstanding (Diluted) | 197 | 197 | 207 | 212 | 206 | 127 |
Shares Change | -3.60% | -4.81% | -2.05% | 2.65% | 62.09% | - |
EPS (Basic) | 0.12 | 0.14 | 0.22 | 0.14 | -0.09 | 0.62 |
EPS (Diluted) | 0.12 | 0.14 | 0.22 | 0.14 | -0.09 | 0.62 |
EPS Growth | -24.97% | -36.98% | 53.11% | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | - | -16.68 | 56.39 | 127.83 | -11.92 | 26.47 |
Free Cash Flow Per Share | - | -0.08 | 0.27 | 0.60 | -0.06 | 0.21 |
Dividend Per Share | 0.150 | 0.150 | - | - | - | - |
Dividend Growth | - | - | - | - | - | - |
Gross Margin | 33.74% | 47.48% | 72.67% | 58.36% | 56.08% | 70.27% |
Operating Margin | 7.28% | 10.75% | 29.30% | 17.66% | -16.75% | 45.83% |
Profit Margin | 6.84% | 10.93% | 27.43% | 19.85% | -12.09% | 33.31% |
Free Cash Flow Margin | - | -6.75% | 34.34% | 84.49% | -8.18% | 11.16% |
EBITDA | 35.34 | 35.8 | 57.24 | 34.97 | -16.08 | 117.05 |
EBITDA Margin | 9.86% | 14.49% | 34.85% | 23.11% | -11.03% | 49.35% |
D&A For EBITDA | 9.25 | 9.24 | 9.12 | 8.26 | 8.33 | 8.36 |
EBIT | 26.09 | 26.57 | 48.12 | 26.71 | -24.4 | 108.69 |
EBIT Margin | 7.28% | 10.75% | 29.30% | 17.66% | -16.75% | 45.83% |
Effective Tax Rate | 20.02% | 17.69% | 16.01% | 16.97% | - | 17.59% |